The organisers of the Totalsports Two Oceans Marathon (TTOM) have announced Cipla as the official Recovery Partner, beginning ...

Jefferies downgraded Syngene to 'underperform' and slashed price target to Rs 480 from Rs 660; JPMorgan downgraded Cipla to ...

Cipla share price falls over 2% after weak Q3FY26 results; profit drops 57% YoY, brokerages cut targets citing US headwinds.

Cipla shares traded lower after the drugmaker reported a sharp year-on-year decline in December-quarter profit, prompting ...

Jan 23 (Reuters) - Cipla, India's third-largest drugmaker by revenue, reported a 57% quarterly profit decline on Friday as ...

In light of Cipla's weak Q3 earnings, brokerages including Goldman Sachs, HSBC, and BofA have all cut target price on the ...

Bata India, Indian Hotels, IGL, MGL, Just Dial, Kalyan Jewellers, Jubilant FoodWorks, Oberoi Realty, Mankind Pharma and ...

Jan 23 (Reuters) - Cipla, India's third-largest drugmaker by revenue, reported a steeper-than-expected 57% fall in quarterly ...

Several brokerages downgraded Cipla following a weaker-than-expected December quarter performance, citing softness in US ...

Net Sales at Rs 7,074.48 crore in December 2025 up 0.02% from Rs. 7,072.97 crore in December 2024. Quarterly Net Profit at Rs. 675.80 crore in December 2025 down 56.97% from Rs. 1,570.51 crore in ...

Cipla Ltd (BOM:500087) reports robust growth in key segments despite facing margin pressures and supply disruptions.